Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter
Harvard Business School

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for SM04690

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug SM04690?

SM04690 is an investigational drug.

There have been 7 clinical trials for SM04690. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Spinal Diseases. The leading clinical trial sponsors are Samumed LLC and [disabled in preview].

There are seven US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for SM04690
TitleSponsorPhase
A Phase 3 Study Utilizing Patient-Reported and Radiograhic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee OsteaoarthritisSamumed LLCPhase 3
A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisSamumed LLCPhase 2
A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisSamumed LLCPhase 2

See all SM04690 clinical trials

Clinical Trial Summary for SM04690

Top disease conditions for SM04690
Top clinical trial sponsors for SM04690

See all SM04690 clinical trials

US Patents for SM04690

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SM04690   Start Trial Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide Samumed, LLC (San Diego, CA)   Start Trial
SM04690   Start Trial Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof Samumed, LLC (San Diego, CA)   Start Trial
SM04690   Start Trial Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof Samumed, LLC (San Diego, CA)   Start Trial
SM04690   Start Trial Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof Samumed, LLC (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SM04690

Drugname Country Document Number Estimated Expiration Related US Patent
SM04690 Australia 2017274350 2036-06-01   Start Trial
SM04690 Brazil 112018074725 2036-06-01   Start Trial
SM04690 Canada 3026076 2036-06-01   Start Trial
SM04690 Chile 2018003423 2036-06-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.